Cyclin D inhibitor therapeutic - Circle Pharma
Alternative Names: Cyclin D RxL inhibitorLatest Information Update: 31 Mar 2025
At a glance
- Originator Circle Pharma
- Class Antineoplastics; Macrocyclic compounds
- Mechanism of Action Cyclin D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 25 Feb 2025 Preclinical trials in Haematological malignancies in USA (unspecified route) prior to February 2025 (Circle Pharma pipeline, February 2025)
- 25 Feb 2025 Preclinical trials in Solid tumours in USA (unspecified route) prior to February 2025 (Circle Pharma pipeline, February 2025)
- 28 Nov 2024 Circle Pharma files for patent protection for 'Cyclin Pharma' in USA